永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a

Guideview > News > Pharmaceutical News > Pfizer's First-Quarter 2024 Financial statements

Pfizer's First-Quarter 2024 Financial statements

Pfizer published its Q1 2024 financial statements on May 1, 2024. GuideView1 MIN READMay 23, 2024


Solid Financial Results

Pfizer Inc. has announced its financial results for the first quarter of 2024, reporting revenues of $14.9 billion. The company's solid performance reflects continued growth in key products and significant progress in executing its 2024 priorities.

Revenue Decline and Growth

The first-quarter results saw a year-over-year operational revenue decrease of 19%, primarily due to the expected decline in revenues from Comirnaty and Paxlovid. However, excluding these contributions, Pfizer achieved an 11% operational revenue growth.

Earnings Per Share

Pfizer reported a first-quarter 2024 diluted EPS of $0.55 and an adjusted diluted EPS of $0.82. These figures include a favorable impact of $0.11 from a final revenue adjustment related to Paxlovid treatment courses returned by the U.S. government.

Cost Savings and Guidance

The company remains on track to deliver at least $4 billion in net cost savings by the end of 2024, as part of its previously announced cost realignment program. Pfizer reaffirmed its full-year 2024 revenue guidance of $58.5 to $61.5 billion and raised its adjusted diluted EPS guidance to $2.15 to $2.35.

Outlook

Pfizer's first-quarter performance underscores its ability to drive growth in key areas despite challenges. The company's commitment to its financial targets and cost-saving initiatives positions it well for continued success throughout 2024.


Highlights

  • Pfizer reported first-quarter 2024 revenues of $14.9 billion.
  • There was a 19% year-over-year operational revenue decrease, mainly due to declining Comirnaty and Paxlovid revenues.
  • Excluding Comirnaty and Paxlovid, operational revenue grew by 11%.
  • Reported diluted EPS for the first quarter was $0.55, with an adjusted diluted EPS of $0.82.
  • The company is on track to achieve at least $4 billion in net cost savings by the end of 2024.
  • Pfizer reaffirmed its full-year 2024 revenue guidance of $58.5 to $61.5 billion and increased its adjusted diluted EPS guidance to $2.15 to $2.35.

Data Source: https://s28.q4cdn.com/781576035/files/doc_financials/2024/q1/Q1-2024-PFE-Earnings-Release.pdf


主站蜘蛛池模板: 久久综合一区二区三区 | 久草91 | 欧美一区二区在线视频 | 韩国美女毛片 | 天天操网站 | 黄片毛片在线观看 | 超碰96 | 亚洲久久天堂 | 免费黄色观看 | chinesemature高潮| 九九热伊人 | 午夜寂寞影院在线观看 | 超碰在线看 | 一级做a爱 | 欧美韩一区二区 | 亚洲日本不卡 | 一级在线| 中国一级片在线观看 | 三级黄视频 | 黄污网站在线观看 | 中文字幕一区2区3区 | 欧美成人精品在线观看 | 欧美美女一区 | 天天色天天色 | 超碰在线公开 | 99色99| 久久综合久久久 | 台湾佬中文字幕 | 亚洲激情视频在线观看 | 黄页av| 久久五月天婷婷 | 深夜av| 中国成人毛片 | 精品成人一区二区 | 一二三区中文字幕 | 日韩在线免费观看视频 | 国产精品九九九九九九 | 中文字幕在线播出 | 成人精品自拍 | 伊人激情 | 麻豆视频91 |